New landmark guidelines from four major medical organizations have put a name to a condition that quietly touches nearly every American adult cardiovascular-kidney-metabolic (CKM) syndrome even as surveys show roughly nine in ten people have never encountered the term.
On June 9, 2026, the American Heart Association (AHA), American College of Cardiology (ACC), American Diabetes Association (ADA), and American Society of Nephrology (ASN) released the first-ever clinical guideline for the diagnosis and management of CKM syndrome. The document is being published simultaneously in Circulation and the Journal of the American College of Cardiology, signaling a new era in medical care for the intertwined threats posed by heart disease, kidney disease, obesity, and diabetes.
It is estimated that almost 90% of the U.S. population has at least one risk factor for CKM syndrome, such as high blood pressure, abnormal cholesterol levels, elevated blood glucose, excess body weight, and/or reduced kidney function. In the United States, 40% of adults and 21% of children and adolescents are obese. That size is still far too small, however, when compared with the results of the AHA’s own Harris Poll, which surveyed approximately 4,000 adults in the United States in August 2025, found that only 12% had ever heard of CKM syndrome or CKM health.
The word is relatively new. In 2023, AHA proposed the term CKM syndrome for an important clinical observation long noted by researchers and clinicians: patients are rarely seen with only one of these conditions. They are clustered together when they arrive. When a person with obesity becomes prediabetic. Prediabetes puts a strain on the kidneys. Kidneys become ineffective, and the blood is flooded with salt and water, increasing blood volume and blood pressure and weakening the heart. A downward spiral which, if not corrected, may lead to a heart event or kidney failure.
The new guideline introduces four stages of the condition, representing a spectrum from early metabolic risk to advanced cardiovascular disease that are associated with CKM syndrome. Stage 1 includes individuals with excess or abnormal fat tissue (BMI 25 or above), as well as individuals with signs of poor glucose tolerance, including prediabetes, with a waist circumference of 88cm or more for women and 102cm or more for men. For Stage 2, metabolic risk factors such as hypertension, high triglycerides, type 2 diabetes, or chronic kidney disease are added. Stage 3 is when people have subclinical cardiovascular disease or a predicted 10-year CVD risk of 20% or more. Stage 4 is clinical cardiovascular disease, with Stage 4b being kidney failure.
There are also guidelines for a “Stage 0” that cover about 10% of Americans who have no current risk factors for the CKM, but who are still at risk.
Brigham and Women’s Hospital cardiologist Muthiah Vaduganathan, a leader in studies of CKM syndrome, carefully explained what the 90% figure does and doesn’t mean. He said that doesn’t mean that 90% of Americans need treatment. It’s more about awareness and early action,” he explained, “I would say 90% of Americans should be aware that they have a risk of developing one or more of these conditions, metabolic, kidney, or heart, and that early lifestyle management can help.
Preventive cardiologist Susan Gilchrist leads the University of North Carolina CKM Syndrome Clinic, and she knows how hard it is to break through the awareness barrier. Patients arrive at her office wondering why they are being referred, all as a result of a framework that’s still very new and that physicians are still learning about.
The 2026 guidelines supersede and build on the 2013 AHA/ACC/TOS guideline on overweight and obesity in adults, which marked a shift in concepts. The old guidance focused on obesity as an isolated risk factor, whereas the new guidance reframes it as a key factor within a system of diseases. This document now includes recommendations for lifestyle advice and weight management, pharmacotherapy (GLP-1 receptor agonists and SGLT2 inhibitors), and, in suitable patients, metabolic and bariatric surgery.
The guideline’s authors said that the CKM is a “paradigm shift” to “less-siloed, more integrated clinical care” for people with multiple, interconnected clinical conditions. Overall, the call is for a coordinated management of the patient, not of each individual organ system.
Cardiologist Kevin Shah, MD, who has written about the new guidelines, said that in the past, we’ve approached heart disease, kidney disease, obesity, and diabetes as separate disease entities. The CKM framework acknowledges that these are interrelated, and if caught early, clinicians can start earlier treatment with lifestyle changes and more effective therapies that can have a long-term impact on the risk of heart-related complications, renal failure, and heart failure.
The PLOS Medicine commentary posed a pertinent question: has the emergence of CKM syndrome actually been a medical breakthrough, or the recasting of what has long been known as the link between heart disease, diabetes, obesity, and kidney dysfunction? But guideline authors say that a formalized relationship alters not just how doctors screen patients, but also when they can intervene.
Although most people don’t know the word, the AHA survey showed that 79% felt it was important to learn more about CKM health, and 72% wanted to learn more about the subject. The most frequently asked questions concerned the diagnosis (71%) and treatment (72%) of CKM syndrome. However, 68% of adults still thought it was better to treat individual conditions, one at a time, as it had been for the past 60 years.
Read Also: What Caused the Drug Recall?
Source: https://www.independent.co.uk/news/health/ckm-syndrome-heart-disease-obesity-kidney-b3012341.html
